OBJECTIVE: Carotid artery stenting (CAS) is emerging as an acceptable treatment alternative to surgery for patients with carotid artery stenosis. The major risk of CAS is cerebral embolization of plaque and thrombus causing stroke or asymptomatic brain infarction. Use of embolic protection devices (EPD) to trap emboli before they reach the brain is now standard practice in CAS. The pore size of the currently available filters is >100 microns and emboli smaller than the EPD pores can still reach the brain. While the use of EPD is widespread, little evidence exists of their in vivo efficacy in preventing distal embolization. Our aim was to quantify the number of emboli reaching the brain with the device in place. Therefore, the expected value of this report is in its description of a novel application of transcranial Doppler (TCD). Due to the limited number of cases, it is not intended to support the use of one EPD over another. METHODS: Six patients were monitored with ipsilateral simultaneous dual probe TCD during CAS. Two types of cerebral protection systems were evaluated: FilterWire EZ System (FW; Boston Scientific, Santa Clara, Calif) and GORE Neuro Protection System (NPS; W.L. Gore and Associates, Flagstaff, Ariz). By placing TCD probes both proximal and distal to the filterwire EPD, we quantified the microembolic signals before the EPD as well as those, which reached the intracranial circulation after the EPD. One probe was placed submandibularly to monitor the ICA (SICA), while another was placed transtemporally to monitor the middle and anterior cerebral artery (MCA + ACA). We compare the number of extracranial emboli prior to the EPD with the number of intracranial emboli after the EPD. RESULTS: Dual probe monitoring was successful during the five stages of the CAS: lesion crossing (LC), predilatation (PreD), stent placement (SP), postdilatation (PostD), and filter/device removal (FR/DR). Using FW during LC by probe 1 (SICA)/probe 2 (MCA + ACA): (18 [range, 15-22]/15 [range, 11-20]), PreD (111 [range, 101-121]/101 [range, 90-111]), SP (68 [range, 60-76]/42 [range, 30-53]), PostD (27 [range, 25-30]/24 [range, 22-27]), FR (0.3 [range, 0-1]/0.7 [range, 0-1]) average number of microembolic signals were detected. Using NPS during LC (1.7 [range, 0-3]/1 [range, 0-2]), PreD (0/1.7 [range, 0-4]), SP (0/0), PostD (0/0), DR (18 [range, 0-18]/6.7 [range, 1-13]) average number of microembolic signals were detected. CONCLUSION: EPD significantly reduces but does not eliminate the number of microemboli reaching the brain during carotid artery angioplasty and stenting. We propose monitoring of CAS with submandibular and transtemporal TCD probes to further evaluate the practice of distal embolization protection. Although our study is not powered to make any recommendations about EPDs, we believe that sequential dual probe TCD monitoring is a worthy tool with the potential to give vital information to assess the various devices and the techniques of utilization.
OBJECTIVE: Carotid artery stenting (CAS) is emerging as an acceptable treatment alternative to surgery for patients with carotid artery stenosis. The major risk of CAS is cerebral embolization of plaque and thrombus causing stroke or asymptomatic brain infarction. Use of embolic protection devices (EPD) to trap emboli before they reach the brain is now standard practice in CAS. The pore size of the currently available filters is >100 microns and emboli smaller than the EPD pores can still reach the brain. While the use of EPD is widespread, little evidence exists of their in vivo efficacy in preventing distal embolization. Our aim was to quantify the number of emboli reaching the brain with the device in place. Therefore, the expected value of this report is in its description of a novel application of transcranial Doppler (TCD). Due to the limited number of cases, it is not intended to support the use of one EPD over another. METHODS: Six patients were monitored with ipsilateral simultaneous dual probe TCD during CAS. Two types of cerebral protection systems were evaluated: FilterWire EZ System (FW; Boston Scientific, Santa Clara, Calif) and GORE Neuro Protection System (NPS; W.L. Gore and Associates, Flagstaff, Ariz). By placing TCD probes both proximal and distal to the filterwire EPD, we quantified the microembolic signals before the EPD as well as those, which reached the intracranial circulation after the EPD. One probe was placed submandibularly to monitor the ICA (SICA), while another was placed transtemporally to monitor the middle and anterior cerebral artery (MCA + ACA). We compare the number of extracranial emboli prior to the EPD with the number of intracranial emboli after the EPD. RESULTS: Dual probe monitoring was successful during the five stages of the CAS: lesion crossing (LC), predilatation (PreD), stent placement (SP), postdilatation (PostD), and filter/device removal (FR/DR). Using FW during LC by probe 1 (SICA)/probe 2 (MCA + ACA): (18 [range, 15-22]/15 [range, 11-20]), PreD (111 [range, 101-121]/101 [range, 90-111]), SP (68 [range, 60-76]/42 [range, 30-53]), PostD (27 [range, 25-30]/24 [range, 22-27]), FR (0.3 [range, 0-1]/0.7 [range, 0-1]) average number of microembolic signals were detected. Using NPS during LC (1.7 [range, 0-3]/1 [range, 0-2]), PreD (0/1.7 [range, 0-4]), SP (0/0), PostD (0/0), DR (18 [range, 0-18]/6.7 [range, 1-13]) average number of microembolic signals were detected. CONCLUSION: EPD significantly reduces but does not eliminate the number of microemboli reaching the brain during carotid artery angioplasty and stenting. We propose monitoring of CAS with submandibular and transtemporal TCD probes to further evaluate the practice of distal embolization protection. Although our study is not powered to make any recommendations about EPDs, we believe that sequential dual probe TCD monitoring is a worthy tool with the potential to give vital information to assess the various devices and the techniques of utilization.
Authors: Ambooj Tiwari; Ryan Bo; Keithan Sivakumar; Karthikeyan M Arcot; Philip Ye; David T Parrella; Jeffrey Farkas Journal: Interv Neurol Date: 2019-08-05